Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma

Baldeep Wirk; Timothy S. Fenske; Mehdi Hamadani; Mei Jie Zhang; Zhen Huan Hu; Görgün Akpek; Mahmoud D. Aljurf; Philippe Armand; Ernesto Ayala; Veronika Bachanova; Brian Bolwell; Mitchell S. Cairo; Amanda Cashen; Yi Bin Chen; Luciano J. Costa; Shatha Farhan; César O. Freytes; James L. Gajewski; John Gibson; Gregory A. Hale; Leona A. Holmberg; Jack W. Hsu; David J. Inwards; Rummurti T. Kamble; Dipnarine Maharaj; Richard T. Maziarz; Reinhold Munker; Rajneesh Nath; Nishitha M. Reddy; Craig B. Reeder; David A. Rizzieri; Craig S. Sauter; Bipin N. Savani; Harry C. Schouten; Anna Sureda; Julie M. Vose; Edmund K. Waller; Peter H. Wiernik; Robert Peter Gale; Linda J. Burns; Wael Saber

doi:10.1016/j.bbmt.2014.03.014

Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma

Baldeep Wirk
, Timothy S. Fenske
, Mehdi Hamadani
, Mei Jie Zhang
, Zhen Huan Hu
, Görgün Akpek
, Mahmoud D. Aljurf
, Philippe Armand
, Ernesto Ayala
, Veronika Bachanova
, Brian Bolwell
, Mitchell S. Cairo
, Amanda Cashen
, Yi Bin Chen
, Luciano J. Costa
, Shatha Farhan
, César O. Freytes
, James L. Gajewski
, John Gibson
, Gregory A. Hale

Leona A. Holmberg, Jack W. Hsu, David J. Inwards, Rummurti T. Kamble, Dipnarine Maharaj, Richard T. Maziarz, Reinhold Munker, Rajneesh Nath, Nishitha M. Reddy, Craig B. Reeder, David A. Rizzieri, Craig S. Sauter, Bipin N. Savani, Harry C. Schouten, Anna Sureda, Julie M. Vose, Edmund K. Waller, Peter H. Wiernik, Robert Peter Gale, Linda J. Burns, Wael Saber

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

There are limited data on the outcomes of autologous or allogeneic hematopoietic cell transplantation (HCT) in diffuse large B cell lymphoma transformed from follicular lymphoma. We analyzed transplantation outcomes in 141 subjects with biopsy-proven diffuse large B-cell lymphoma transformed from follicular lymphoma reported to the Center for International Blood and Marrow Transplant Research between 1990 and 2009. Two groups were identified: autologous HCT (auto-HCT; n = 108) and allogeneic HCT (allo-HCT; n = 33). Fewer auto-HCTs were done for transformed follicular lymphoma in 2003 to 2009, with a shift favoring allo-HCT. Auto-HCT was associated with a 1-year nonrelapse mortality (NRM) of 8% (95% confidence interval [CI], 4% to 14%), 5-year progression-free survival of 35% (95% CI, 26% to 45%), and 5-year overall survival of 50% (95% CI, 40% to 59%). In contrast, allo-HCT was associated with a 1-year NRM of 41% (95% CI, 23% to 58%), 5-year progression-free survival of 18% (95% CI, 6% to 35%), and 5-year overall survival of 22% (95% CI, 8% to 41%). Auto-HCT for transformed follicular lymphoma achieves sustained remission in a high proportion of subjects. The high NRM of allo-HCT offset any benefit that might be associated with this transplantation modality.

Original language	English
Pages (from-to)	951-959
Number of pages	9
Journal	Biology of Blood and Marrow Transplantation
Volume	20
Issue number	7
DOIs	https://doi.org/10.1016/j.bbmt.2014.03.014
State	Published - Jul 2014

Funding

Financial disclosure: The Center for International Blood and Marrow Transplant Research is supported by Public Health Service Grant/Cooperative Agreement U24 CA076518 from the National Cancer Institute (NCI) , the National Heart, Lung and Blood Institute (NHLBI) , and the National Institute of Allergy and Infectious Diseases ; Grant/Cooperative Agreement U10 HL069294 from the NHLBI and NCI ; Contract HHSH250201200016C with Health Resources and Services Administration; Grants N00014-12-1-0142 and N00014-13-1-0039 from the Office of Naval Research; and grants from Allos Therapeutics, Amgen, anonymous donation to the Medical College of Wisconsin, Ariad, Be the Match Foundation, Blue Cross and Blue Shield Association, Celgene, Fresenius-Biotech North America, Gamida Cell Teva Joint Venture, Genentech, Gentium, Genzyme, GlaxoSmithKline, HistoGenetics, Kiadis Pharma, Leukemia & Lymphoma Society, Medical College of Wisconsin, Merck & Co, Millennium: Takeda Oncology, Milliman USA, Miltenyi Biotec, National Marrow Donor Program, Onyx Pharmaceuticals, Optum Healthcare Solutions, Osiris Therapeutics, Otsuka America Pharmaceutical, Remedy Informatics, Sanofi US, Seattle Genetics, Sigma-Tau Pharmaceuticals, Soligenix, StemCyte, Stemsoft Software, Swedish Orphan Biovitrum, Tarix Pharmaceuticals, TerumoBCT, Teva Neuroscience, Therakos, and Wellpoint. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, Department of the Navy, Department of Defense, or any other agency of the US Government.

Funders	Funder number
Fresenius Biotech North America
Merck
Teva Neuroscience, Inc.
Office of Naval Research Naval Academy
National Heart, Lung, and Blood Institute (NHLBI)
National Childhood Cancer Registry – National Cancer Institute
National Institute of Allergy and Infectious F32-AI286447 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R01AI168214 Jason W. Rosch Diseases National Institute of Allergy and Infectious P30 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R00-AI166116 Christopher D. Radka Diseases National Institute of Allergy and Infectious T32-AI106700 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R01AI192221 Jason W. Rosch Diseases National Inst...	N00014-13-1-0039, U10 HL069294, HHSH250201200016C, N00014-12-1-0142
Be The Match Foundation
AMGen
National Center for Advancing Translational Sciences (NCATS)	KL2TR000113
Celgene
Blue Cross and Blue Shield Association
Allos Therapeutics

Keywords

Transformed follicular lymphoma
Transplant

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1016/j.bbmt.2014.03.014

Cite this

Wirk, B., Fenske, T. S., Hamadani, M., Zhang, M. J., Hu, Z. H., Akpek, G., Aljurf, M. D., Armand, P., Ayala, E., Bachanova, V., Bolwell, B., Cairo, M. S., Cashen, A., Chen, Y. B., Costa, L. J., Farhan, S., Freytes, C. O., Gajewski, J. L., Gibson, J., ... Saber, W. (2014). Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma. Biology of Blood and Marrow Transplantation, 20(7), 951-959. https://doi.org/10.1016/j.bbmt.2014.03.014

@article{ec9ed97987a04c05ac96f0130ee0fc8c,

title = "Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma",

abstract = "There are limited data on the outcomes of autologous or allogeneic hematopoietic cell transplantation (HCT) in diffuse large B cell lymphoma transformed from follicular lymphoma. We analyzed transplantation outcomes in 141 subjects with biopsy-proven diffuse large B-cell lymphoma transformed from follicular lymphoma reported to the Center for International Blood and Marrow Transplant Research between 1990 and 2009. Two groups were identified: autologous HCT (auto-HCT; n = 108) and allogeneic HCT (allo-HCT; n = 33). Fewer auto-HCTs were done for transformed follicular lymphoma in 2003 to 2009, with a shift favoring allo-HCT. Auto-HCT was associated with a 1-year nonrelapse mortality (NRM) of 8\% (95\% confidence interval [CI], 4\% to 14\%), 5-year progression-free survival of 35\% (95\% CI, 26\% to 45\%), and 5-year overall survival of 50\% (95\% CI, 40\% to 59\%). In contrast, allo-HCT was associated with a 1-year NRM of 41\% (95\% CI, 23\% to 58\%), 5-year progression-free survival of 18\% (95\% CI, 6\% to 35\%), and 5-year overall survival of 22\% (95\% CI, 8\% to 41\%). Auto-HCT for transformed follicular lymphoma achieves sustained remission in a high proportion of subjects. The high NRM of allo-HCT offset any benefit that might be associated with this transplantation modality.",

keywords = "Transformed follicular lymphoma, Transplant",

author = "Baldeep Wirk and Fenske, \{Timothy S.\} and Mehdi Hamadani and Zhang, \{Mei Jie\} and Hu, \{Zhen Huan\} and G{\"o}rg{\"u}n Akpek and Aljurf, \{Mahmoud D.\} and Philippe Armand and Ernesto Ayala and Veronika Bachanova and Brian Bolwell and Cairo, \{Mitchell S.\} and Amanda Cashen and Chen, \{Yi Bin\} and Costa, \{Luciano J.\} and Shatha Farhan and Freytes, \{C{\'e}sar O.\} and Gajewski, \{James L.\} and John Gibson and Hale, \{Gregory A.\} and Holmberg, \{Leona A.\} and Hsu, \{Jack W.\} and Inwards, \{David J.\} and Kamble, \{Rummurti T.\} and Dipnarine Maharaj and Maziarz, \{Richard T.\} and Reinhold Munker and Rajneesh Nath and Reddy, \{Nishitha M.\} and Reeder, \{Craig B.\} and Rizzieri, \{David A.\} and Sauter, \{Craig S.\} and Savani, \{Bipin N.\} and Schouten, \{Harry C.\} and Anna Sureda and Vose, \{Julie M.\} and Waller, \{Edmund K.\} and Wiernik, \{Peter H.\} and Gale, \{Robert Peter\} and Burns, \{Linda J.\} and Wael Saber",

year = "2014",

month = jul,

doi = "10.1016/j.bbmt.2014.03.014",

language = "English",

volume = "20",

pages = "951--959",

number = "7",

}

Wirk, B, Fenske, TS, Hamadani, M, Zhang, MJ, Hu, ZH, Akpek, G, Aljurf, MD, Armand, P, Ayala, E, Bachanova, V, Bolwell, B, Cairo, MS, Cashen, A, Chen, YB, Costa, LJ, Farhan, S, Freytes, CO, Gajewski, JL, Gibson, J, Hale, GA, Holmberg, LA, Hsu, JW, Inwards, DJ, Kamble, RT, Maharaj, D, Maziarz, RT, Munker, R, Nath, R, Reddy, NM, Reeder, CB, Rizzieri, DA, Sauter, CS, Savani, BN, Schouten, HC, Sureda, A, Vose, JM, Waller, EK, Wiernik, PH, Gale, RP, Burns, LJ & Saber, W 2014, 'Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma', Biology of Blood and Marrow Transplantation, vol. 20, no. 7, pp. 951-959. https://doi.org/10.1016/j.bbmt.2014.03.014

TY - JOUR

T1 - Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma

AU - Wirk, Baldeep

AU - Fenske, Timothy S.

AU - Hamadani, Mehdi

AU - Zhang, Mei Jie

AU - Hu, Zhen Huan

AU - Akpek, Görgün

AU - Aljurf, Mahmoud D.

AU - Armand, Philippe

AU - Ayala, Ernesto

AU - Bachanova, Veronika

AU - Bolwell, Brian

AU - Cairo, Mitchell S.

AU - Cashen, Amanda

AU - Chen, Yi Bin

AU - Costa, Luciano J.

AU - Farhan, Shatha

AU - Freytes, César O.

AU - Gajewski, James L.

AU - Gibson, John

AU - Hale, Gregory A.

AU - Holmberg, Leona A.

AU - Hsu, Jack W.

AU - Inwards, David J.

AU - Kamble, Rummurti T.

AU - Maharaj, Dipnarine

AU - Maziarz, Richard T.

AU - Munker, Reinhold

AU - Nath, Rajneesh

AU - Reddy, Nishitha M.

AU - Reeder, Craig B.

AU - Rizzieri, David A.

AU - Sauter, Craig S.

AU - Savani, Bipin N.

AU - Schouten, Harry C.

AU - Sureda, Anna

AU - Vose, Julie M.

AU - Waller, Edmund K.

AU - Wiernik, Peter H.

AU - Gale, Robert Peter

AU - Burns, Linda J.

AU - Saber, Wael

PY - 2014/7

Y1 - 2014/7

N2 - There are limited data on the outcomes of autologous or allogeneic hematopoietic cell transplantation (HCT) in diffuse large B cell lymphoma transformed from follicular lymphoma. We analyzed transplantation outcomes in 141 subjects with biopsy-proven diffuse large B-cell lymphoma transformed from follicular lymphoma reported to the Center for International Blood and Marrow Transplant Research between 1990 and 2009. Two groups were identified: autologous HCT (auto-HCT; n = 108) and allogeneic HCT (allo-HCT; n = 33). Fewer auto-HCTs were done for transformed follicular lymphoma in 2003 to 2009, with a shift favoring allo-HCT. Auto-HCT was associated with a 1-year nonrelapse mortality (NRM) of 8% (95% confidence interval [CI], 4% to 14%), 5-year progression-free survival of 35% (95% CI, 26% to 45%), and 5-year overall survival of 50% (95% CI, 40% to 59%). In contrast, allo-HCT was associated with a 1-year NRM of 41% (95% CI, 23% to 58%), 5-year progression-free survival of 18% (95% CI, 6% to 35%), and 5-year overall survival of 22% (95% CI, 8% to 41%). Auto-HCT for transformed follicular lymphoma achieves sustained remission in a high proportion of subjects. The high NRM of allo-HCT offset any benefit that might be associated with this transplantation modality.

AB - There are limited data on the outcomes of autologous or allogeneic hematopoietic cell transplantation (HCT) in diffuse large B cell lymphoma transformed from follicular lymphoma. We analyzed transplantation outcomes in 141 subjects with biopsy-proven diffuse large B-cell lymphoma transformed from follicular lymphoma reported to the Center for International Blood and Marrow Transplant Research between 1990 and 2009. Two groups were identified: autologous HCT (auto-HCT; n = 108) and allogeneic HCT (allo-HCT; n = 33). Fewer auto-HCTs were done for transformed follicular lymphoma in 2003 to 2009, with a shift favoring allo-HCT. Auto-HCT was associated with a 1-year nonrelapse mortality (NRM) of 8% (95% confidence interval [CI], 4% to 14%), 5-year progression-free survival of 35% (95% CI, 26% to 45%), and 5-year overall survival of 50% (95% CI, 40% to 59%). In contrast, allo-HCT was associated with a 1-year NRM of 41% (95% CI, 23% to 58%), 5-year progression-free survival of 18% (95% CI, 6% to 35%), and 5-year overall survival of 22% (95% CI, 8% to 41%). Auto-HCT for transformed follicular lymphoma achieves sustained remission in a high proportion of subjects. The high NRM of allo-HCT offset any benefit that might be associated with this transplantation modality.

KW - Transformed follicular lymphoma

KW - Transplant

UR - https://www.scopus.com/pages/publications/84902084890

UR - https://www.scopus.com/pages/publications/84902084890#tab=citedBy

U2 - 10.1016/j.bbmt.2014.03.014

DO - 10.1016/j.bbmt.2014.03.014

M3 - Article

C2 - 24641828

AN - SCOPUS:84902084890

SN - 1083-8791

VL - 20

SP - 951

EP - 959

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 7

ER -

Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this